Aldeyra Therapeutics Sued in Securities Class Action Over Reproxalap Trial Disclosures

Overview

• Rosen Law Firm says it filed a class action for Aldeyra shareholders who bought ALDX between November 3, 2023 and March 16, 2026.
• DJS Law Group and Bronstein, Gewirtz & Grossman urged investors to contact them about joining the case and seeking lead‑plaintiff roles.
• The complaints allege Aldeyra misled the market by promoting reproxalap, an eye‑drug candidate, despite clinical trials that produced inconsistent results.
• DJS cites claims under Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5 for alleged false or misleading statements.
• No class has been certified, so investors are not represented unless they hire a lawyer, and they can still share in any recovery if a class is later approved.